Raypal Biomedical Co., Ltd.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. Comprehensive GTP-Grade Cell Processing Laboratory
2. Immune Cell Therapy: Cytokine-Induced Killer Cells (CIK); Dendritic Cell-Activated Cytokine-Induced Killer Cells (DC-CIK); Natural Killer Cells (NK); Dendritic Cells (DC)
3. Regenerative Medicine: Exosomes (Exosome); Mesenchymal Stem Cells (MSC); Adipose-Derived Stem Cells (ADSC)
4. Cosmetics/Healthcare: DR.REAL Zhen Yang; EVs Intelligent Skin Revitalizing Six-Step Routine: (I) Makeup Removal/Cleansing; EVs Intelligent Skin Revitalizing Six-Step Routine: (II) Toner
5. Scientific Research / Clinical Collaboration: Chondrocyte Cell-Sheets; Safety and Efficacy Evaluation of Cytokine-Induced Killer Cells in the Treatment of Advanced Liver Cancer
(The content above was translated by AI.)
2. Immune Cell Therapy: Cytokine-Induced Killer Cells (CIK); Dendritic Cell-Activated Cytokine-Induced Killer Cells (DC-CIK); Natural Killer Cells (NK); Dendritic Cells (DC)
3. Regenerative Medicine: Exosomes (Exosome); Mesenchymal Stem Cells (MSC); Adipose-Derived Stem Cells (ADSC)
4. Cosmetics/Healthcare: DR.REAL Zhen Yang; EVs Intelligent Skin Revitalizing Six-Step Routine: (I) Makeup Removal/Cleansing; EVs Intelligent Skin Revitalizing Six-Step Routine: (II) Toner
5. Scientific Research / Clinical Collaboration: Chondrocyte Cell-Sheets; Safety and Efficacy Evaluation of Cytokine-Induced Killer Cells in the Treatment of Advanced Liver Cancer
(The content above was translated by AI.)
Founded Year
2016
Unified Business No.
43807841
Status
Active
Number of Employees
0
Total Paid-in
Capital
154,871,430 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Raypal Biomedical Co., Ltd. was founded in May 2016. Adhering to the corporate spirit of "active research, excellent innovation, and serving humanity," the company is dedicated to the research and development of cancer immune cell therapy and stem cell regenerative medicine. In March 2018, the company received approval from the Ministry of Health and Welfare to conduct Phase I and Phase II cell therapy clinical trials for the "Evaluation of the Safety and Efficacy of Cytokine-Induced Killer Cells in the Treatment of Advanced Hepatocellular Carcinoma." In January 2022, the company officially inaugurated the "first cell preparation center in southern Taiwan - Kaohsiung Medical University Hospital-Raypal Cell Therapy Laboratory," and began setting up a PIC/S GMP-grade cell preparation center in the Neihu Technology Park in Taipei City. In December 2023, the company was approved by the Department of Medical Affairs of the Ministry of Health and Welfare to collaborate with Tungs' Taichung MetroHarbor Hospital in executing "Autologous Immune Cell CIK Therapy for Stage IV Solid Tumors."
(The content above was translated by AI.)
(The content above was translated by AI.)
